We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Implement Diagnostics System Improves Infectious Disease Testing

By LabMedica International staff writers
Posted on 17 Dec 2019
A team of scientists recently began using machine-learning tools and assessed them in a prospective clinical trial to determine whether artificial intelligence could perform better than specialists in clinical test interpretation.

The tool automates and standardizes quantitative polymerase chain reaction (PCR) test analysis, enabling real-time monitoring on a test-by-test basis. More...
The company developed the machine-learning system in part to address shortages of trained laboratory staff, as well as to help laboratories improve internal efficiencies, both in terms of time and money saved.

Scientists from Glasgow Royal Infirmary (Glasgow, UK) undertook a prospective clinical study to evaluate the accuracy and impact when automating the manual data-analysis and quality control steps associated with routine clinical pathogen testing using real-time PCR (qPCR). They evaluated the use of the tool when used as a final interpretation and verification step for routine in-house qPCR tests for respiratory pathogens and for norovirus for a total of 22,200 interpretations. The tests were run over the course of a month. The tool is called PCR.ai and is produced by Diagnostics.ai (London, UK).

The team reported that there was 100% concurrence between validated respiratory virus and norovirus detection by their manual routine analysis method and PCR.Ai. Furthermore, there were significant routine savings with PCR.ai of 45 min/respiratory run and 32 min/norovirus run. They concluded that PCR.ai is a highly accurate time-saving tool that reduces complexity of qPCR analysis and hence the need for specialists and hands-on time. It demonstrated capabilities to enable the scientists to get results out more quickly with lower costs and less risk of errors.

Typically, the company works with a lab's existing data, which is fed to the learning machine during a training phase. Any inconsistencies are flagged and dealt with during an interactive phase. Once completed, PCR.ai is handed off to users to run in real-time on a standalone server that is not accessible to the firm. Revenues are derived via a service and support model, influenced by volumes and support needs. The firm's emphasis, however, is on reducing costs within laboratories.

Aron Cohen, BA, CEO of Diagnostics.ai, said, “The model, especially in the UK, tends to be savings driven. I think that's an important approach we have taken, that in addition to improving quality and accuracy, turnaround time, and getting better results faster, reducing costs is a vital piece of that puzzle. Some places have six- or seven-day weeks including night shifts. We need to be able to provide support for that. It's important to have the resources to be able to cope. I think taking in over 20,000 results, and proving we could do it faster, with no errors, and even picking up mistakes made in the manual process are really impressive results for any clinical or AI product.” The study was published in the November, 2019 issue of the Journal of Clinical Virology.

Related Links:
Glasgow Royal Infirmary
Diagnostics.ai


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: MPNST is a cancer of the connective tissue surrounding peripheral nerves, with NF1 being a key risk factor (Image Credit: Nephron/Wikimedia Commons (CC BY-SA 3.0)

Liquid Biopsy Shows Promise for Detecting and Monitoring Malignant Nerve Sheath Tumors

Malignant peripheral nerve sheath tumor (MPNST) is one of the most serious cancers affecting people with neurofibromatosis type 1 (NF1), yet timely recognition remains difficult. Clinicians often struggle... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.